HDAC9 and cancer: Notably, combinationstudies in T-PLL patient samples demonstrated KT-531 synergizes withapproved cancer drugs, bendamustine, idasanutlin, and venetoclax.Our work suggests HDAC inhibition in T-PLL could afford sufficienttherapeutic windows to achieve durable remission either as stand-aloneor in combination with targeted drugs.